Concepedia

Li Zheng

LZ

Statistics

Publications

8

Citations

512

H-Index

8

Active since

2018

Affiliations

AstraZeneca (United Kingdom)(Current)

Institut Català d'Oncologia

Institut Gustave Roussy

University of California San Diego

Stockholm County Council

Li Zheng is an author at AstraZeneca (United Kingdom) specializing in oncology, medicine, and cancer pharmacology.

Publications per year

2018–2025

8

Publications

8

The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models

Stephen T. Durant, Li Zheng, Yingchun Wang et al. · Science Advances · 2018 · 312 citations · Full text

Medicine, Nuclear Medicine, Oncology +17

Orally Bioavailable and Blood–Brain Barrier-Penetrating ATM Inhibitor (AZ32) Radiosensitizes Intracranial Gliomas in Mice

Jeremy Karlin, Jasmine Allen, Syed Farhan Ahmad et al. · Molecular Cancer Therapeutics · 2018 · 61 citations · Full text

Medicine, Oncology, Pharmacology +16

Pt–Se Hybrid Nanozymes with Potent Catalytic Activities to Scavenge ROS/RONS and Regulate Macrophage Polarization for Osteoarthritis Therapy

Hong Wei, Hongjun Huang, Haoqiang He et al. · Research · 2024 · 56 citations · Full text

Life Sciences, Biotechnology, Pharmacology +17

Clinicopathological characteristics and prognostic factors of pulmonary sarcomatoid carcinoma: a large population analysis

Qiao Yan, Xiang Song, Li Zheng et al. · Annals of Translational Medicine · 2021 · 21 citations · Full text

Medicine, Geriatric Medicine, Oncology +10

A multinational pivotal study of sunvozertinib in platinum pretreated non-small cell lung cancer with EGFR exon 20 insertion mutations: Primary analysis of WU-KONG1 study.

James Chih‐Hsin Yang, Ludovic Doucet, Mengzhao Wang et al. · Journal of Clinical Oncology · 2024 · 20 citations

Medicine, Oncology, Pharmacology +14

1–5 of 8